Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Argus Health
Harvard Business School
Chinese Patent Office
Mallinckrodt
Chubb
Johnson and Johnson
Moodys
Deloitte

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,316,997

« Back to Dashboard

Which drugs does patent 7,316,997 protect, and when does it expire?

Patent 7,316,997 protects EGRIFTA and is included in one NDA.

This patent has eighteen patent family members in eleven countries.
Summary for Patent: 7,316,997
Title:GH secretagogues and uses thereof
Abstract:The invention relates to use of a GH secretagogue (e.g. GRF or an analog thereof) for (1) altering a lipid parameter in a subject; (2) altering a body composition parameter in a subject, (3) treating a condition characterized by deficient or decreased bone formation in a subject (4) improving daytime vigilance and/or cognitive function in a subject, (5) improving a metabolic condition in a subject, (6) improving anabolism in a catabolic condition in a subject, and/or (7) improving and/or reconstituting immune function in a subject.
Inventor(s): Abribat; Thierry (St-Foy-les-Lyon, FR), De Villers; Andre (Outremont, CA), Allas; Soraya (Iles Des Soeurs, CA), Gravel; Denis (Saint-Lambert, CA), Chapdelaine; Alcide (Iles Des Soeurs, CA)
Assignee: Theratechnologies Inc. (Ville Saint-Laurent, CA)
Application Number:10/969,463
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,316,997

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-001 Nov 10, 2010 RX Yes Yes ➤ Sign Up ➤ Sign Up REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY ➤ Sign Up
Theratechnologies EGRIFTA tesamorelin acetate POWDER;SUBCUTANEOUS 022505-002 Nov 29, 2011 DISCN No No ➤ Sign Up ➤ Sign Up REDUCTION OF EXCESS ABDOMINAL FAT IN HIV-INFECTED PATIENTS WITH LIPODYSTROPHY ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,316,997

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,481,489 GH secretagogues and uses thereof ➤ Sign Up
8,314,066 GH secretagogues and uses thereof ➤ Sign Up
8,435,945 GH secretagogues and uses thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Boehringer Ingelheim
McKinsey
Chinese Patent Office
Teva
Covington
Merck
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.